XU Xiangyu 1,2,3 , YUAN Lei 1,2,3 , SUN Fei 1,2,3 , SHEN Zhiming 1,2,3 , SHAN Yibo 1,2,3 , LU Yi 1,2,3 , ZHU Jianwei 1,2,3 , CHEN Wenxuan 1,2,3 , SHI Hongcan 1,2,3
  • 1. Clinical Medical College, Yangzhou University, Yangzhou, 225009, Jiangsu, P. R. China;
  • 2. Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, 225009, Jiangsu, P. R. China;
  • 3. Jiangsu Key Laboratory of Integrated Traditional Chinese and Western Medicine for Prevention and Treatment of Senile Diseases, Yangzhou University, Yangzhou, 225009, Jiangsu, P. R. China;
SHI Hongcan, Email: shihongcan@yzu.edu.cn
Export PDF Favorites Scan Get Citation

Objective  To analyze the current research application status and hotspots of nanoparticles in the treatment of non-small cell lung cancer (NSCLC) and predict the future development trend. Methods The Web of Science database was searched for literatures on nanoparticles use in the treatment of NSCLC from inception to November 2022. CiteSpace, VOSviewer and literature measurement analysis online platform (https://bibliometric.com/) were used for the visual analysis of the number of documents, source journals, authors, organizations, countries and keywords. Results A total of 742 English literatures were included. The results showed that the number of published literatures increased year by year from 2011 and reached the peak in 2020. Researches on nanoparticles and NSCLC treatment were mainly concentrated in China, the United States, India and Japan. China is a major research country in this field, but it lacked cooperation with other countries and related institutions. Among numerous research institutions, the Chinese Academy of Sciences was the authoritative and backbone force in this research field, with the number of published literatures ranking first and the research achievements outstanding. The keyword analysis found that "poly lactic-co-glycolic acid nanoparticles (PLGA NPs)" and "photothermal therapy" had become the latest breakout words since 2018. Moreover, the occurrence frequency of related keywords such as "drug delivery" increased significantly, indicating that the application of PLGA NPs in photothermal therapy might be the current research hotspot and future development trend of NSCLC treatment. Conclusion Currently, the domestic research on the treatment of nanoparticles and NSCLC is in a leading position in the world. The organic combination of nanoparticles with different materials and other NSCLC therapies is expected to improve the prognosis of NSCLC patients. In the future, attempts to develop nanoparticles with different sources and structures and combined with photothermal therapy for the treatment of NSCLC may become a research hotspot of nanoparticles in the treatment of NSCLC.

Citation: XU Xiangyu, YUAN Lei, SUN Fei, SHEN Zhiming, SHAN Yibo, LU Yi, ZHU Jianwei, CHEN Wenxuan, SHI Hongcan. A bibliometric analysis of nanoparticles in the treatment of non-small cell lung cancer. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2024, 31(8): 1139-1147. doi: 10.7507/1007-4848.202212017 Copy

  • Previous Article

    Application of mammary-duct exenteration of nipple-skin-sparing mastectomy for breast cancer: A prospective cohort study
  • Next Article

    Predictive value of cardiopulmonary exercise test in the postoperative complications in patients with esophageal cancer: A retrospective cohort study